Shares of Mallinckrodt PLC (NYSE:MNK) have received a consensus recommendation of “Buy” from the nineteen analysts that are presently covering the stock, Analyst Ratings Network.com reports. Two investment analysts have rated the stock with a sell recommendation, five have issued a hold recommendation, ten have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $101.38.

Mallinckrodt PLC (NYSE:MNK) traded up 0.70% during mid-day trading on Friday, hitting $57.70. 1,542,279 shares of the company were exchanged. Mallinckrodt PLC has a 12-month low of $52.01 and a 12-month high of $134.26. The company has a 50 day moving average of $68.97 and a 200 day moving average of $79.02. The stock has a market cap of $6.69 billion and a P/E ratio of 20.97.

Mallinckrodt PLC (NYSE:MNK) last released its earnings results on Monday, November 23rd. The company reported $1.84 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.77 by $0.07. The company had revenue of $882.40 million for the quarter, compared to analyst estimates of $869.41 million. During the same quarter in the previous year, the firm earned $1.59 EPS. The firm’s revenue was up 31.0% on a year-over-year basis. On average, equities research analysts expect that Mallinckrodt PLC will post $7.83 earnings per share for the current fiscal year.

In other news, SVP Coleman N. Lannum III purchased 500 shares of the stock in a transaction dated Tuesday, December 22nd. The shares were purchased at an average cost of $72.50 per share, with a total value of $36,250.00. Following the completion of the acquisition, the senior vice president now owns 11,266 shares in the company, valued at approximately $816,785. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Mark Trudeau purchased 1,350 shares of the stock in a transaction dated Monday, November 30th. The stock was purchased at an average cost of $65.89 per share, for a total transaction of $88,951.50. Following the completion of the acquisition, the chief executive officer now owns 167,526 shares of the company’s stock, valued at approximately $11,038,288.14. The disclosure for this purchase can be found here.

Other large investors have recently made changes to their positions in the company. Janus Capital Management increased its stake in shares of Mallinckrodt PLC by 5.5% in the third quarter. Janus Capital Management now owns 8,456,040 shares of the company’s stock worth $540,681,000 after buying an additional 437,392 shares during the last quarter. ICON Advisers increased its stake in shares of Mallinckrodt PLC by 27.9% in the third quarter. ICON Advisers now owns 44,001 shares of the company’s stock worth $2,813,000 after buying an additional 9,600 shares in the last quarter. Private Trust Company increased its stake in shares of Mallinckrodt PLC by 48.0% in the fourth quarter. Private Trust Company now owns 6,371 shares of the company’s stock worth $475,000 after buying an additional 2,065 shares in the last quarter. Fourth Swedish National Pension Fund increased its stake in shares of Mallinckrodt PLC by 4.9% in the fourth quarter. Fourth Swedish National Pension Fund now owns 24,042 shares of the company’s stock worth $1,794,000 after buying an additional 1,122 shares in the last quarter. Finally, Capstone Asset Management Company increased its stake in shares of Mallinckrodt PLC by 20.0% in the fourth quarter. Capstone Asset Management Company now owns 14,195 shares of the company’s stock worth $1,059,000 after buying an additional 2,370 shares in the last quarter.

A number of research analysts recently issued reports on MNK shares. Oppenheimer reiterated a “buy” rating and set a $138.00 target price on shares of Mallinckrodt PLC in a research report on Tuesday, October 6th. Guggenheim reiterated a “buy” rating and set a $130.00 target price on shares of Mallinckrodt PLC in a research report on Tuesday, October 6th. Deutsche Bank reiterated a “buy” rating and set a $89.00 target price (down previously from $104.00) on shares of Mallinckrodt PLC in a research report on Wednesday, October 7th. Bank of America dropped their target price on shares of Mallinckrodt PLC from $135.00 to $131.00 and set a “buy” rating on the stock in a research report on Wednesday, October 7th. Finally, Mizuho started coverage on shares of Mallinckrodt PLC in a research note on Friday, October 9th. They set a “neutral” rating and a $67.00 price target for the company.

Mallinckrodt public limited company (NYSE:MNK) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Company’s Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Company’s Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product.

12 Month Chart for NYSE:MNK

Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.